Today, OFTIM celebrates its 80th episode and presents its ESMO23 plenary session, including two practice-changing, paradigm-shifting trials. The first investigates the EGFR mutation Non-Small Cell Lung Cancer world with new drugs (amivantamab and lazertinib) to treat patients hose who progressed on osimertinib. The second trial is the EV-302/KEYNOTE-A39, which explores whether enfortumab vedotin (ADC) and pembrolizumab (immunotherapy) can best-platinum-based chemotherapy. No prior trial has ever done this, so the stakes are high. As the little engine once said, "I think I can", and, we, too, continue to see seismic shifts in cancer treatment in our quest for better therapy.
For now, the OFTIM team is signing out and taking a small break after daily reporting, but we hope you loved it and can't wait to return with more from the fascinating world of Medical Oncology.
Studies
EV-302/KEYNOTE-A39 - https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639614
MARIPOSA-2 - https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639283
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us atinquisitiveonc@gmail.com
Art courtesy of Taryn Silver
Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Hosted on Acast. See acast.com/privacy for more information.
お客様へのおすすめ
